Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT03712566 Not yet recruiting - Cancer Clinical Trials

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

MASST
Start date: October 2018
Phase:
Study type: Observational

This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.

NCT ID: NCT03711422 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Start date: October 2018
Phase: Phase 1
Study type: Interventional

Brain metastases occurs in up to 50% of patients with EGFR mutant NSCLC. Leptomeningeal disease is a subset of patients with brain metastases for which there remains an unmet need. This trial aims to evaluate the role of two dosing schedules of afatinib in management of leptomeningeal disease in EGFR mutant NSCLC, specifically to determine Central Nervous System (CNS) penetration of afatinib, as well as clinical activity. Patients will start on daily dosing initially followed by pulsed intermittent dosing should we observe no clinical activity. A secondary objective is to identify the resistance spectrum in leptomeningeal disease. It is anticipated that optimal dosing schedule of afatinib e.g. pulsed dosing may improve CNS disease control.

NCT ID: NCT03711240 Not yet recruiting - Colorectal Cancer Clinical Trials

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

CBL
Start date: October 22, 2018
Phase: Phase 2
Study type: Interventional

This single-arm study will evaluate the resection rate of liver metastases in patients with metastatic colorectal cancer and borderline unresectable liver metastases receiving treatment with bevacizumab in combination with modified-FOLFOXIRI as first line treatment. Patients will receive bevacizumab (5 mg/kg) plus modified-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 46-h continuous infusion) every 14 days as neoadjuvant chemotherapy regimen. This study treatment will continue until surgery, disease progression, unacceptable toxicity, or patient refusal.

NCT ID: NCT03705403 Not yet recruiting - Metastatic Disease Clinical Trials

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

IMMUNOSABR2
Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

This will be a phase II trial testing if the combination of stereotactic body radiation therapy (SBRT) and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm. Patients with oligometastatic disease will receive stereotactic body radiotherapy to all metastatic sites (max 3 sites irradiated) and patients with diffuse metastatic lesions (max 10) will receive radiotherapy to max 3 sites. In the experimental arm, immunotherapy will be given after irradiation.

NCT ID: NCT03703167 Not yet recruiting - Clinical trials for Primary Central Nervous System Lymphoma (PCNSL)

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Start date: November 2018
Phase: Phase 1
Study type: Interventional

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

NCT ID: NCT03698461 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

CLIMB
Start date: December 2018
Phase: Phase 2
Study type: Interventional

Liver is the most common site of metastases from colorectal cancer. Neoadjuvant chemotherapy with targeted agents is usually recommended for borderline-resectable liver metastases that are technically difficult to resect for conversion to resectable disease and control of metastatic spread. However, the prognosis of these patients are still poor, and long term disease-free survival over 3 years is rare and <20%. More effective measures to prevent recurrence are needed before or after resection of colorectal liver metastases.

NCT ID: NCT03698162 Not yet recruiting - Metastatic Melanoma Clinical Trials

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

Start date: November 12, 2018
Phase: N/A
Study type: Interventional

Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high grade glioma that has come back or melanoma that has spread to the brain. The specially-tailored acquisition and reconstruction (STAR) DCE MRI could provide improved assessment of brain tumor status and response to therapy.

NCT ID: NCT03697343 Not yet recruiting - Clinical trials for Cerebral Metastases of Solid Cancers

Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases

Start date: January 2019
Phase: Phase 3
Study type: Interventional

Phase III trial comparing local control and side effects after fractionated stereotactic radiotherapy and single session radiosurgery in patients with larger brain metastases (2-4 cm)

NCT ID: NCT03697304 Not yet recruiting - Neoplasm Metastasis Clinical Trials

Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the efficacy of BI 754091 in combination with other checkpoint inhibitors or anticancer medications in diverse tumour type cohorts.

NCT ID: NCT03697044 Not yet recruiting - Liver Metastases Clinical Trials

Irinotecan Drug-eluting Bead Liver Embolisation Registry

DLivERDEBIRI
Start date: January 2019
Phase:
Study type: Observational [Patient Registry]

Purpose: The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery of this drug compares to worldwide/European guidelines, and to determine which individual variations in delivery may be associated with an increased complication profile or better outcome. The aim of the study is to: 1. Prospectively evaluate the number of centres providing DEBIRI 2. To determine the number of patients being treated nationally per year 3. To evaluate individual variations in practice with respect to number of treatments, method of pain control, side effect profile, and complication profile. 4. To collect patient specific data subsets to allow correlation and causal associations between these individual variations, and relate these to efficacy and survival during the study period.